Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Pravibismane for Moderate Diabetic Foot Infection
NCT05174806Phase 2Completed
- Sponsor
- Microbion
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diabetic foot infection (DFI) comparing Topical Pravibismane (MBN-101) with Standard of Care (2 arms). Primary endpoint: Proportion of patients with adverse events at 12 weeks. Started Jun 2022; status: completed.
02
Drugs
pravibismane
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on NCT05174806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174806.